- Previous Close
123.15 - Open
125.95 - Bid 128.75 x --
- Ask 129.20 x --
- Day's Range
125.25 - 128.65 - 52 Week Range
115.05 - 313.65 - Volume
2,933 - Avg. Volume
14,326 - Market Cap (intraday)
11.832B - Beta (5Y Monthly) 0.13
- PE Ratio (TTM)
25.71 - EPS (TTM)
5.00 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield 0.50 (0.41%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
--
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients (APIs) and formulations for use in various therapeutic areas, including anti-tuberculosis, anti-malarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition, anaesthesia, gynecology, and orthopedics. It also offers anti-inflammatory drugs and other drugs. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India.
www.themismedicare.com1,509
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: THEMISMED.BO
View MorePerformance Overview: THEMISMED.BO
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: THEMISMED.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: THEMISMED.BO
View MoreValuation Measures
Market Cap
11.33B
Enterprise Value
11.92B
Trailing P/E
24.63
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.66
Price/Book (mrq)
2.75
Enterprise Value/Revenue
2.79
Enterprise Value/EBITDA
15.28
Financial Highlights
Profitability and Income Statement
Profit Margin
10.69%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.32B
Net Income Avi to Common (ttm)
461.41M
Diluted EPS (ttm)
5.00
Balance Sheet and Cash Flow
Total Cash (mrq)
176.02M
Total Debt/Equity (mrq)
19.77%
Levered Free Cash Flow (ttm)
--